Mammalian Cells News and Research

RSS

Origene Technologies' acquisition of Marligen Biosciences reinforces its leading position in the bio-medical research industry

OriGene Technologies, Inc. today announced the acquisition of Marligen Biosciences, Inc., a provider of cutting-edge multiplex assays for the Luminex xMAP(R) platform for protein and gene expression profiling assays and testing services, and DNA and RNA purification kits.

20 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

BioReliance Corporation announced today that it has launched a fully validated assay which can sensitively detect the presence of Calicivirus 2117 in biological samples. The test is designed to provide manufacturers of biological therapeutics and other biologically based products the ability to detect this potential contaminant of mammalian cell culture based systems.

7 Oct 2009

Nanodiamonds advance anticancer gene therapy

Gene therapy holds promise in the treatment of cancer as well as a large number of other diseases. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging. Now, two teams of researchers have developed versatile nanotechnology-enabled platforms that could get therapeutic genes safely and efficiently into cancer cells.

23 Sep 2009

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets in multiple therapeutic areas. The alliance will capitalize on Ambrx's recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates.

19 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

Insects can be used to test the efficiency of new drugs

Insects, such as some moths and fruit flies, react to microbial infection in the same way as mammals and so can be used to test the efficiency of new drugs, thereby reducing the need for animal testing. Dr Kevin Kavanagh from the National University of Ireland - Maynooth, presented his research findings at the Society for General Microbiology's meeting at Heriot Watt University, Edinburgh, today (8 September).

7 Sep 2009

BF STEM tomography allows to visualize fine details of cell structure

Scientists in the National Institute of Biomedical Imaging and Bioengineering (NIBIB) Laboratory of Bioengineering and Physical Science have developed a new technique that allows researchers to visualize fine details of cell structure three-dimensionally in thick sections, thus providing greater insight into how cells are organized and how they function. The work is described in a report published online this week in Nature Methods.

4 Sep 2009

Nanodiamonds: A novel gene delivery technology

Gene therapy holds promise in the treatment of a myriad of diseases, including cancer, heart disease and diabetes, among many others. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging.

2 Sep 2009

New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

Cytovance Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Dr. Jeffrey Su as Vice President of Bioanalytical Development to its diverse and growing scientific staff. Dr. Su will head up the state of the art Bioanalytical Development laboratory supporting existing and new client needs.

1 Sep 2009

OriGene Technologies releases recombinant proteins purified from HEK293 cells

OriGene Technologies, Inc. announces the release of 5,000 purified human proteins, representing the most comprehensive offering of human cell-produced human proteins.

25 Aug 2009

New "micropatterning" method useful in gene expression studies

Like oil and water, two water-based liquids can mingle without mixing in a new University of Michigan technology developed for biological experiments.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

Stemcells, Inc. reports Q2 financials

Results for the quarter reflect the Company’s acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.

10 Aug 2009

Americans come up with first swine flu vaccine

The company based in Connecticut, Protein Sciences Corporation, won a $35-million government contract to develop an influenza vaccine using insect cell technology and Protein Sciences's director Dan Adams says the first batch of about 100,000 doses were produced last week and the manufacture of the vaccine continues.

24 Jun 2009